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Abstract
Background: The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common
neurodegenerative disorders including Parkinson’s disease. One widely explored therapeutic strategy for these
conditions is the use of antibodies to target aggregated ɑS, although a detailed molecular-level mechanism
of the action of such species remains elusive. Here, we characterize ɑS aggregation in vitro in the presence
of two ɑS-specific single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which bind to the highly
accessible C-terminal region of ɑS.
Results: We show that both nanobodies inhibit the formation of ɑS fibrils. Furthermore, using single-molecule
fluorescence techniques, we demonstrate that nanobody binding promotes a rapid conformational conversion from
more stable oligomers to less stable oligomers of ɑS, leading to a dramatic reduction in oligomer-induced cellular
toxicity.
Conclusions: The results indicate a novel mechanism by which diseases associated with protein aggregation can be
inhibited, and suggest that NbSyn2 and NbSyn87 could have significant therapeutic potential.
Keywords: Protein aggregation, Amyloid toxicity , Neurodegeneration, Aggregation inhibitors, Antibody, Single-
molecule fluorescence
Background
The aberrant aggregation of the protein ɑ-synuclein (ɑS)
has been linked to the onset and progression of Parkin-
son’s disease (PD), dementia with Lewy bodies [1], PD
dementia, multiple system atrophy, and related synu-
cleopathies [2–4]. The histopathological characteristics
of PD and its associated disorders include the presence
of neuronal inclusions, for example, Lewy bodies and
Lewy neurites, which are primarily composed of fibrillar
ɑS [1, 5]. The deposition of ɑS in the nervous system
follows a characteristic pattern [6], and the ability of
aggregated species to propagate across the brain by a
mechanism that is defined as prion-like is increasingly
recognized [7]. In aqueous solution, monomeric ɑS
self-assembles into amyloid fibrils resembling those
that are deposited in the brain, and the aggregation
process proceeds through the formation of intermediate
species, including soluble oligomers, prior to fibril forma-
tion [8, 9]. Moreover, these oligomeric species, rather than
mature amyloid fibrils, have increasingly been identified as
the most highly neurotoxic forms of ɑS [10–16].
As a consequence of the central role of ɑS aggregation
in PD and the neurotoxicity of its assemblies, immuno-
therapy against ɑS is being widely pursued as a potential
disease-modifying strategy [17, 18]. Although passive
immunization using antibodies targeting ɑS has shown
promise in numerous in vitro and in vivo model systems,
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as well as in several clinical trials [19, 20], there is no ef-
fective treatment for PD and other synucleinopathies. In
order to make significant advances in this objective, it is
crucial to develop a detailed understanding of the mo-
lecular mechanism of action of ɑS-specific antibodies
during the aggregation process of the protein.
Over the years, full-length antibodies and antibody
fragments, such as scFvs, have been generated against
different regions and different species of ɑS for either
biophysical studies, target validation, or therapy
(reviewed in De Genst et al. [21] and Bergstrom et al.
[20]), and have been used in multiple reported studies
[22–27].
Full-length ɑS consists of 140 amino acid residues di-
vided into three distinct regions, namely a positively
charged lipid-binding N-terminal segment comprising
residues 1–60, a central hydrophobic segment consisting
of residues 61–95, and a negatively-charged C-terminal
region comprising residues 96–140 [28]. This latter re-
gion does not include the residues observed to be in the
amyloid fibril core [29], although previous in vitro stud-
ies have shown that its deletion promotes ɑS aggregation
[30], indicating its involvement in the aggregation
process. Notably, antibodies directed to the C-terminal
region of ɑS, or specific for oligomeric forms of ɑS, were
reported both to suppress strongly its aggregation and to
reduce cellular toxicity [24, 27].
We have previously described two single-domain frag-
ments of camelid heavy-chain antibodies [31], termed
‘nanobodies’ [32], denoted NbSyn2 [33] and NbSyn87 [34],
which bind to distinctive epitopes within the C-terminal
region of monomeric ɑS (residues 137–140 and 118–131,
respectively). These nanobodies, which were raised against
and bind to monomeric ɑS, also recognize fibrillar forms of
ɑS in which the C-terminal region is exposed [29], allowing
the use of these nanobodies as biophysical probes to study
the properties of ɑS fibrils [34]. Moreover, one of these
nanobodies, NbSyn87, when expressed as a genetic fusion
protein with a PEST proteasomal degradation tag, was
found to reduce toxicity in cell-lines overexpressing ɑS
as a result of the specific degradation of monomeric
ɑS, thereby significantly reducing proteostatic stress
[35].
In order to understand such phenomena in molecular
detail, it is important to characterize the impact of nano-
body binding on the overall ɑS aggregation process in
vitro, and in particular its effect on the formation of the
highly toxic oligomers that are linked to cellular damage.
It is known from previous studies that the C-terminal
region of ɑS is exposed in at least some of its aggregated
intermediate forms, such as oligomers [36], as well as
monomers and fibrils, and that targeting of this region by
antibodies has been recognized to have protective effects
[19]. Therefore, it is plausible that the nanobodies and
other C-terminal-binding antibodies can affect the forma-
tion and properties of these oligomers.
Since the pre-fibrillar oligomers are generally transient
and heterogeneous, and are typically present at very low
concentrations relative to ɑS monomers, they are diffi-
cult to study by conventional bulk techniques. We have
previously utilized single-molecule Förster resonance
energy transfer (sm-FRET) measurements in order to
characterize the oligomerization of ɑS in considerable
detail [13, 37]. Using this technique, we identified two
distinct types of ɑS oligomers that were populated
sequentially prior to the formation of ɑS fibrils [13]. The
two oligomer types had distinct FRET efficiency distri-
butions and were therefore termed “low-FRET” and
“high-FRET” oligomers [13]. The differences in their
photophysical properties, as well as their different kinet-
ics of formation, stabilities towards dissociation and
enzymatic proteolysis, and toxicity to cells indicated that
these two oligomer forms were structurally distinct
intermediates generated in the process of the formation
of ɑS fibrils [13, 38]. In particular, the initial assembly of
low-FRET oligomers was followed by slow conformational
conversion into high-FRET oligomers prior to fibril for-
mation. The accumulation of high-FRET oligomers was
associated with the highest level of cytotoxicity, pointing
to this specific oligomer type as the most damaging
species formed during ɑS aggregation.
In this study, we set out to characterize in detail the
effects of NbSyn2 and NbSyn87 on the aggregation of ɑS
in vitro. First, we investigated fibril formation using a
combination of biophysical experiments to monitor the
kinetics of this process, and compared the properties of
the various resulting fibrillar aggregates. Second, we
employed sm-FRET techniques to explore how the pres-
ence of NbSyn87 and NbSyn2 affects the formation of
the low-FRET and high-FRET oligomers. We identi-
fied the ability of the nanobodies to inhibit the for-
mation of ɑS fibrils and to destabilize toxic high-FRET
oligomers of ɑS, and explored how the latter process af-
fects oligomer-induced cytotoxicity.
Results
NbSyn2 and NbSyn87 inhibit the formation, maturation,
and elongation of ɑS fibrils
We first investigated the effects of the ɑS-specific nano-
bodies, NbSyn87 and NbSyn2, on ɑS fibril formation. To
determine whether or not the binding of nanobodies to
the C-terminal region affects the aggregation propensity
of ɑS, we initially performed bulk solution aggregation
assays to monitor fibril formation by full-length wild-
type (wt) ɑS using thioflavin T (ThT) fluorescence mea-
surements to monitor the quantity of aggregated ɑS. In
these experiments, ɑS at a concentration of 70 μM was
aggregated in the absence or presence of 140 μM
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NbSyn2, NbSyn87, or a control nanobody, cAbHuL5g
(NbHul5g) [39]; the latter is a lysozyme-specific nano-
body [39] and is therefore not expected to bind to ɑS.
From Eq. 1 (Methods), taking the dissociation constants
of NbSyn2 and NbSyn87 for monomeric ɑS, respectively,
as approximately 264 nM and 42 nM [34] at 37 °C, we
calculated that the free ɑS concentration under these con-
ditions was approximately 260 nM and 40 nM, respect-
ively, thereby approximating full saturation of all ɑS
binding sites. The samples were incubated at physiologic-
ally relevant pH and ionic strengths (as detailed in the
Methods section) at 37 °C with agitation to promote fi-
bril formation; the resulting kinetic profiles of fibril
formation are shown in Fig. 1a.
The aggregation kinetics of ɑS in the absence of
nanobodies are in good agreement with our previ-
ously reported bulk kinetic measurements of ɑS under
similar incubation conditions [13, 37]. In contrast,
moderate inhibition of fibril formation was observed
in the presence of NbSyn2, whereas solutions incu-
bated in the presence of NbSyn87 gave rise to much
lower ThT fluorescence signals over the entire dur-
ation of the experiment, indicating a stronger inhib-
ition of ɑS fibril formation in the presence of this
nanobody [13, 37]. In addition, we confirmed the in-
hibition of the formation of ThT-active aggregates in
the presence of NbSyn2 and NbSyn87 by total in-
ternal reflection fluorescence microscopy imaging of
the solutions extracted during the process of the ag-
gregation reaction (Additional file 1: Figure S1).
Subsequently, we characterized the end products of
aggregation using atomic force microscopy (AFM). In
agreement with the findings from the ThT fluores-
cence assays, the images obtained in this way showed
the presence of large numbers of amyloid fibrils in
the solutions of ɑS that had been incubated in the
absence of nanobodies or in the presence of NbHul5g
or NbSyn2 (Fig. 1b). In the samples of ɑS incubated
with NbSyn87, only small and apparently spherical
aggregates along with monomeric species were observed,
and no large fibrils could be detected (Fig. 1b).
Comparison of average fibril heights from AFM maps
revealed that fibrils formed in the presence of NbSyn2
were thinner than fibrils formed in the absence of
nanobodies or in the presence of NbHul5g (Fig. 1c
and Additional file 1: Figure S1), indicating that nanobo-
dies impaired the maturation of ɑS fibrils. The differ-
ences in the fibril-forming capability of ɑS identified
in the presence of the two ɑS-specific nanobodies
might be due to the differences in the epitopes they
bind. NbSyn87 binds with higher affinity and closer
to the NAC region than does NbSyn2, and thereby
might slow fibril formation due to steric hindrance
and promote the formation of smaller fibrils (Fig. 1b).
We also performed quartz crystal microbalance experi-
ments [40, 41] in order to measure the effects of NbSyn2
and NbSyn87 on the elongation rates of pre-formed ɑS
fibrils upon their incubation with either monomeric ɑS,
or with a stoichiometric ratio of monomeric ɑS and
NbSyn87, NbSyn2, or NbHul5g (Additional file 2). It
was found that the elongation rate of ɑS fibrils markedly
decreased in the presence of both ɑS-specific nanobo-
dies, corresponding to 30–40% of the rate in their ab-
sence, as described in further detail in Additional file 2:
Tables S3 and S4, and discussed in Additional file 2:
Supplementary Results.
NbSyn2 and NbSyn87 impede the generation of high-FRET
oligomeric species of ɑS prior to fibril formation
Having characterized the impact of the ɑS-specific nano-
bodies on the formation of ɑS fibrils, we subsequently
set out to focus on the earlier steps in the ɑS aggregation
reaction and to determine whether or not nanobodies
affected oligomer formation. To this end, we used sm-
FRET techniques developed in previous studies of the
aggregation of ɑS in aqueous solution [13, 37, 38]. In
sm-FRET experiments, an alanine to cysteine mutation
at residue 90 of ɑS (A90C) was introduced to enable the
attachment of a single Alexa Fluor (AF) dye; we have
previously shown that this modification does not sig-
nificantly influence the kinetics of ɑS fibril formation
[13, 37, 38], a conclusion additionally confirmed in the
present study by bulk ThT assays using wt and AF-labeled
ɑS (Additional file 3: Figure S2a). Because residue 90 is
located at the periphery of the central amyloidogenic re-
gion of the ɑS molecule [28], AF dyes come into close
proximity during fibril formation. We have used AF488
and AF594 dyes, which we have found are sufficiently
close together within the aggregates for FRET to be de-
tectable, the efficiency of which is a useful readout of the
aggregation reaction (Eq. 2, Methods). This approach
makes it possible to detect two distinct oligomer types,
those with a low FRET efficiency and those giving rise
to a higher FRET efficiency, both of which are ob-
served prior to fibril formation [13, 37, 38]. The sm-
FRET analysis is selective for oligomeric aggregates and
excludes large fibrillar species formed later during the
aggregation process (as detailed in Methods and dem-
onstrated in previous studies [13, 37, 38]). Therefore,
this technique is complementary to the bulk ThT assay
that has been used to monitor fibril formation (Fig. 1a).
For every oligomer detected in the experiment, the FRET
efficiency value and the apparent size in monomer units
were calculated according to Eqs. 2 and 3 (Methods).
These data are represented in Fig. 2 as histograms to show
both the numbers and properties of the oligomer
distributions.
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In sm-FRET experiments, equimolar mixtures of AF488-
labeled ɑS (AF488-ɑS) and AF594-labeled ɑS (AF594-ɑS)
were used at a total protein concentration of 70 μM, either
in the presence or absence of 140 μM of unlabeled
nanobodies. The solutions were incubated with agitation
under the same conditions as in the bulk ThT assays, and
aliquots were withdrawn at regular time intervals during
the incubation, diluted 105-fold to generate appropriate
Fig. 1 Aggregation kinetics of 70 μM ɑS in the absence and presence of nanobodies. a Bulk kinetic profiles of fibril formation, monitored by ThT
fluorescence (n = 3, mean ± SEM). b Representative AFM images of the samples where the aggregation reaction had reached steady state (107 h);
images of the samples prior to initiation of the aggregation reaction are shown in Additional file 1: Figure S1a. c Histograms representing the values of
average fibril heights from AFM analysis. Scatter plots and statistical comparisons of these distributions are given in Additional file 1:
Figure S1c. d sm-FRET kinetic profiles derived from monomer depletion (n = 6, mean ± SEM) and oligomer formation (at least n = 3,
mean ± SEM) of ɑS at 70 μM in aqueous buffer, in the presence of 140 μM of the control NbHul5g (e), and in the presence of ɑS-spe-
cific nanobodies (f and g)
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conditions for single-molecule detection, and immediately
analyzed by sm-FRET. We analyzed the solutions both fol-
lowing their dilution into aqueous buffer of the same com-
position as that used for the incubations (PBS, see in
Methods), and following dilution into deionized water; we
have recently shown that dilution into low ionic strength
solutions enables an improved separation of the low- and
high-FRET oligomers [38]. We measured the average
brightness of AF488-ɑS and AF594-ɑS in the presence of
the unlabeled nanobodies to verify that the nanobodies did
not affect the fluorescence properties of the dyes in the
sm-FRET experiments (Additional file 2: Supplementary
Information). In addition, we carried out control experi-
ments using samples where both ɑS and nanobodies were
labeled with AF to confirm that the nanobodies were fully
dissociated from ɑS during the detection step under both
solution conditions; the results were consistent with previ-
ously reported Kd values [34], as detailed in Additional file 2:
Supplementary Methods and Tables S1 and S2.
The resulting kinetic profiles of ɑS monomer depletion
and oligomer formation are shown in Fig. 1d–g. The
most rapid decrease in the monomer concentration,
deduced from the monomer burst-rates [37], occurred
in the samples containing 70 μM ɑS alone or in the
Fig. 2 Representative FRET efficiency histograms obtained for different time points during the first 30 h of aggregation, recorded upon dilution into
deionized water for sm-FRET detection. Here, the histograms have been split into two populations of apparent sizes, small-mers (2–5 monomer
units) and large-mers (6–150 monomer units). For large-mers, the differences in the FRET efficiency histograms are clearly observable, espe-
cially at times longer than 24 h. In the histograms of ɑS-only and ɑS with NbHul5g, the peak centered at the FRET efficiency value of 0.8 is
dominant and corresponds to high-FRET oligomers. In the presence of both ɑS-specific nanobodies, the histograms are centered at the FRET
efficiency value of 0.5, and the maximum at 0.8 is absent
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presence of the control NbHul5g (Fig. 1d, e). However,
samples containing NbSyn87 and NbSyn2 showed sig-
nificantly slower monomer depletion. Based on the
monomer depletion data derived from sm-FRET, after
30 h of aggregation, approximately 70% of the sample
was aggregated in the ɑS-only reaction, 90% in the ɑS
plus control nanobody, and approximately 40% in the
samples containing both ɑS and NbSyn87 or NbSyn2.
The oligomers were formed in all samples, and
comprised less than 2% of the samples of ɑS (Fig. 1d–g).
Transmission electron microscopy (TEM) images of
the samples at incubation times longer than 100 h con-
firmed the presence of abundant quantities of amyloid
fibrils in the solutions containing ɑS alone or in the
presence of NbHul5g and of NbSyn2, while only oligo-
mers and short protofibrils were detected in the pres-
ence of NbSyn87 (Additional file 3: Figure S2b). These
results confirm that the nanobodies inhibit ɑS fibril for-
mation, and are therefore in good agreement with the
bulk ThT fluorescence data and AFM results obtained
for wt unlabeled ɑS as detailed above (Fig. 1b).
To elucidate the effects of the nanobodies on the
formation of the low-FRET and high-FRET oligomers,
individual FRET efficiency histograms of the samples re-
corded following dilution into water were analyzed.
These showed clear differences between the control
samples and the samples containing ɑS-specific NbSyn2
and NbSyn87 (Fig. 2). As in our previous work [13, 37],
we separated the FRET efficiency histograms into two
groups, corresponding to the histograms derived from
“small” oligomers containing 2–5 apparent monomer
units (denoted as “small-mers”) and oligomers contain-
ing 6–150 apparent monomer units (“large-mers”), based
on the number of peaks that were resolvable in the
FRET efficiency histograms, as previously reported [37].
This procedure allows us to identify the time-dependent
changes readily, which are most clearly evident in the
histograms for the large oligomers formed during
aggregation (Fig. 2).
For the samples of ɑS alone, and ɑS in the presence of
control NbHul5g, two peaks could be observed in the
FRET efficiency histograms of the large-mers (Fig. 2),
corresponding to the two previously identified oligomer
populations [13, 37, 38]. Low-FRET oligomers are char-
acterized by a population centered at an average FRET
efficiency value (E) of 0.5, and high-FRET oligomers are
indicated by the peak centered at E value of approxi-
mately 0.8 (Fig. 2). The high-FRET population was
clearly distinguishable after 24 h of aggregation and was
dominant by 30 h of incubation both in the absence of
nanobodies and in the presence of the control nanobody
(Fig. 2), in good agreement with our previously reported
kinetics of high-FRET oligomer formation [13, 37]. The
mild acceleration of the formation of high-FRET species
in the presence of the control nanobody NbHul5g com-
pared to the ɑS-only sample might be due to the crowd-
ing effect or transient interactions of NbHul5g with ɑS.
Instead of exhibiting two populations at times longer
than 24 h, however, the FRET histograms of oligomers
formed in the presence of ɑS-specific nanobodies
showed a single broad peak. The appearance of these
histograms resembles those that had been obtained
previously for ɑS solutions at low concentrations, in
which high-FRET oligomers were not formed at high
levels, yet were not fully absent [37]. Therefore, the
appearance of the FRET efficiency histograms suggests
that, in the presence of ɑS-specific nanobodies, the for-
mation of high-FRET oligomers is impeded.
To characterize quantitatively the observed differences
in ɑS oligomer populations either in the absence or pres-
ence of the nanobodies, we carried out a detailed kinetic
analysis by fitting the experimental aggregation profiles
to a nucleation-conversion-polymerization model similar
to that reported previously [37]. A description of the
analysis and the rate constants obtained for the individ-
ual microscopic steps of the aggregation process are
available in Additional file 2: Supplementary Information
and Additional file 4: Figure S3. We achieved the closest
agreement with experimental data by assuming that both
of the ɑS-specific nanobodies accelerate the reverse
microscopic reaction steps, i.e., the conformational
conversion from high-FRET oligomers to low-FRET
oligomers and subsequently to monomers. This increase
in rate results in the net inhibition of the overall forward
aggregation process in the presence of NbSyn2 and
NbSyn87, and successfully explains the experimentally
observed reduced proportion of high-FRET oligomers
and the altered kinetics of monomer depletion and fibril
formation. Furthermore, this analysis predicted the
distinct accumulation of low-FRET oligomers over lon-
ger aggregation times (Additional file 4: Figure S3). In
the following section we discuss direct evidence for
these phenomena.
NbSyn2 and NbSyn87 enhance the conversion of high-FRET
into low-FRET oligomeric species
Having characterized the kinetics of ɑS aggregation in
the presence of NbSyn2 and NbSyn87, we set out to
obtain direct evidence to support the conclusion that
the nanobodies could promote the conformational con-
version step from high-FRET to low-FRET species. To
this end, we tested whether or not the addition of the
nanobodies promoted the dissociation of pre-formed
high-FRET oligomeric species. For these experiments,
solutions from the aggregation reactions of 70 μM la-
beled ɑS in the absence of nanobodies were collected
after 29 h of incubation and analyzed by sm-FRET to
monitor the presence of high-FRET oligomers.
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Subsequently, two molar equivalents of unlabeled
NbSyn2, NbSyn87 or NbHul5g were added to these sam-
ples prior to sm-FRET measurement. The representa-
tive contour plots of FRET efficiencies and apparent
oligomer sizes, as well as the FRET efficiency histo-
grams of each sample (Fig. 3) show highly reprodu-
cible results as nearly identical outcomes were
observed in at least five independent experiments
where fresh nanobodies were added to pre-formed
high-FRET oligomers. The addition of NbSyn2 or
NbSyn87 resulted in a reproducible decrease of the
mean FRET efficiency values (Fig. 3b). These changes
in FRET efficiencies cannot be explained by optical
effects, e.g., quenching of fluorescence due to the
binding of the nanobodies to the oligomeric species,
because the samples were diluted by a factor of 105,
bringing the concentration of the NbSyn87 and
NbSyn2 significantly below the Kd values of the inter-
action of the nanobodies with monomeric ɑS, as in
all previous sm-FRET measurements [34]. In addition,
the koff values for NbSyn87 and NbSyn2 are the order
of 0.01 and 0.1 s–1, respectively (Additional file 2:
Supplementary Methods), indicating that the complexes
would dissociate upon dilution, an assumption that was
confirmed by the experimentally observed absence of
coincidence between the labeled nanobody and ɑS under
our detection conditions.
The changes in FRET efficiency values following the
addition of NbSyn2 or NbSyn87 can therefore be attrib-
uted solely to the nanobody-induced conformational
conversion of the high-FRET oligomers to the less-
ordered low-FRET oligomers, in agreement with the re-
sults of the kinetic analysis. This conversion process was
particularly fast in the presence of NbSyn87, with a rate
constant of 1.0 ± 0.5 h–1 (Additional file 4: Figure S3);
the more highly pronounced effect of NbSyn87 com-
pared to NbSyn2 in this experiment is attributable to its
higher affinity for ɑS. The oligomers will remain in the
low-FRET structure during the analysis as the conform-
ational reorganization from low-FRET to high-FRET
oligomers in the absence of the nanobodies is character-
ized by a high energy barrier, reflected in a half-time of
several hours [13].
The conformational conversion from high- to low-
FRET oligomers described here was observed upon the
addition of two molar equivalents of nanobodies. We
also carried out titrations to determine the lowest stoi-
chiometric ratio of the nanobodies to ɑS at which this
behavior is observable. The reduction in FRET efficien-
cies in this experiment could be clearly observed down
Fig. 3 Results of sm-FRET measurements after addition of two equivalents of unlabeled nanobodies to pre-formed high-FRET oligomers. The
oligomers were pre-formed by the aggregation of 70 μM ɑS without nanobodies for 29 h under the same incubation conditions as for the
sm-FRET kinetic assays. a Representative contour plots of FRET efficiency versus apparent oligomer size resulting from sm-FRET measurements per-
formed immediately after addition of nanobodies to aggregated solutions of ɑS (after 29 h). b Corresponding FRET efficiency histograms split into two
size populations, small (2- to 5-mers) and large (6- to 150-mers) species. In the absence of nanobodies and upon addition of the control NbHul5g, the
majority of the large oligomeric species observed in the experiment had FRET efficiency values above 0.6, characteristic of high-FRET oligomers (first
two panels). Upon addition of either NbSyn2 (third panel) or NbSyn87 (fourth panel), the average FRET efficiency distributions shifted to lower values,
an effect that was particularly pronounced in the presence of NbSyn87
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to 0.5 molar equivalents of the nanobodies, while at
concentrations below 0.25 molar equivalents this
process was too slow to be observed even upon
incubation for 10 h (Additional file 5: Figure S4).
The reduced population of high-FRET oligomers in the
presence of NbSyn87 and NbSyn2 leads to significantly
reduced cellular damage
The observation that NbSyn2 and NbSyn87 impair the
formation of high-FRET oligomer types during the
aggregation process and induce a more rapid conform-
ational conversion of pre-formed high-FRET oligomers
into low-FRET species, prompted us to test if these
effects could result in an overall decrease in the average
stability and cytotoxicity of the oligomers generated at
the early stages of the aggregation process of ɑS.
It has previously been shown that high-FRET oligo-
mers are more resistant towards digestion by proteinase
K than are low-FRET oligomers, an observation that
serves as an additional indication of the structural differ-
ences between these two oligomer types [13]. To deter-
mine whether or not the populations of oligomers
formed in the presence of the nanobodies were more
susceptible to proteinase K digestion than these formed
in their absence, we exposed ɑS samples after 29 h of
incubation under aggregating conditions to varying
concentrations of proteinase K. The resulting digestion
profiles are shown in Fig. 4a, and representative contour
plots of FRET efficiencies and size distributions de-
rived for individual samples in this assay are given in
Additional file 6: Figure S5. From Fig. 4a, the popula-
tions of oligomeric species formed in the presence of
NbSyn2 or NbSyn87 were more susceptible to proteinase
K digestion than those formed in the presence of
NbHul5g. This result is consistent with a lower proportion
of more compact high-FRET oligomers in the solutions
Fig. 4 Comparative assays showing the relative stability and cytotoxicity of ɑS oligomers generated after aggregation for 29 h in the presence or
absence of nanobodies under the same conditions as for the sm-FRET measurements. a Sm-FRET proteinase K digestion assays. The fraction of
degradation is the number of oligomers in the proteinase K-exposed sample divided by the number of oligomers in the initial sample (n = 3, mean
± SD). Additional file 6: Figure S5 shows representative contour plots of FRET efficiencies versus apparent oligomer sizes. b Degradation of the 29 h
samples by the 26S proteasome over 24 h (n = 3, SD, P < 0.05), analyzed by sm-FRET. c Cytoplasmic reactive oxygen species (ROS) production mea-
sured by monitoring the rate of dihydroethidium fluorescence (detailed in Additional file 2: Supplementary Methods). Application of ɑS oligomers
to mixed cultures of rat hippocampal and cortical neurons (500 nM of total ɑS) induced an increase in the rate of ROS production rela-
tive to a control with no ɑS (taken as 100%); ɑS alone (n = 76 cells); ɑS with NbHul5g (n = 66 cells); ɑS with NbSyn2 (n = 89 cells, P <
0.001); and ɑS with NbSyn87 (n = 54 cells, P < 0.01). Additional file 8: Figure S6 shows representative plots of dihydroethidium fluorescence
versus time. d Percentage cell death, measured by propidium iodide staining after incubation with the different ɑS oligomeric species. Cell death in
the absence of ɑS (buffer control, n = 6 coverslips); upon incubation with ɑS alone (100 nM total ɑS, n = 7 coverslips); with ɑS with NbSyn2 (n = 5 cov-
erslips, P < 0.001); with ɑS with NbSyn87 (n = 8 coverslips, P < 0.05). e Quantification of the released pro-inflammatory cytokine TNF-ɑ in BV2 microglia
after the application of 29 h timepoints of ɑS (10 μM of the total ɑS), aggregated in the absence of nanobodies (n = 3, SEM), in the presence of 2 molar
equivalents of NbHul5g (n = 3, SEM, P < 0.05), NbSyn2 (n = 3, SEM, P < 0.01), or NbSyn87 (n = 3, SEM, P < 0.001), and incubation with the cells for 24 h
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containing NbSyn2 and NbSyn87 than in the presence of
NbHul5g, supporting the sm-FRET findings on the rates
of interconversion. Subsequently, we measured whether
or not the aggregates generated during the 29 h incuba-
tion period in the presence of ɑS-specific nanobodies were
more degradable in comparison to the aggregates formed
in the presence of the control nanobody by exposing these
samples to the 26S proteasome for 24 h, and quantifying
the numbers of non-degraded oligomers by sm-FRET, as
described fully in Additional file 2: Supplementary Infor-
mation. The results of this experiment indicate that the
oligomer populations formed in the presence of the two
specific nanobodies could be degraded by the proteasome
to a greater extent than the aggregates formed in the
presence of the control nanobody (Fig. 4b).
We then investigated if the inhibitory effect of the
nanobodies at early stages of the aggregation reaction
could result in a change in oligomer-induced cellular
damage. High-FRET oligomers have been found in pre-
vious studies to induce significantly higher levels of
cellular toxicity in rat mid-brain neuronal cultures than
the low-FRET species [13, 37, 42]. Aliquots were ex-
tracted from samples of ɑS undergoing aggregation in
the absence or presence of nanobodies after incubation
for 29 h, and the production of reactive oxygen species
(ROS) was measured following the application of these
solutions to primary co-cultures of neurons and
astrocytes (Additional file 2: Supplementary Informa-
tion). The results show that the presence of NbSyn87 or
NbSyn2 led to a significantly reduced rate of ROS pro-
duction in comparison to the samples generated in their
absence or in the presence of the control nanobody
NbHul5g (Fig. 4c). This observed reduction in the
oligomer-induced ROS indicates a reduced proportion of
toxic high-FRET oligomers and supports the sm-FRET
and proteinase K digestion results described above. We
also investigated the ability of ɑS oligomer populations
prepared in the presence or absence of nanobodies to in-
duce cell death (see Additional file 2: Supplementary In-
formation for details).
We found that the incubation of cells with ɑS aggre-
gated in the presence of either NbSyn87 or NbSyn2 led
to a significant reduction in cell death in comparison to
the incubation of ɑS alone (Fig. 4d), indicating in the
former the presence of a lower proportion of high-FRET
compared to low-FRET oligomers. Apart from the
significantly reduced cytotoxicity upon application of
nanobody-bound oligomers in comparison to the oligo-
mers of ɑS alone in ROS and cell death assays, it was
found that the samples containing NbSyn2 reduced the
cytotoxicity more effectively in comparison to NbSyn87
(Fig. 4c, d). While the overall reduction of cytotoxicity in
comparison to the ɑS-only samples is entirely consistent
with the measured ability of NbSyn87 and NbSyn2 to
convert toxic high-FRET oligomers to low-FRET oligo-
mers in aqueous solution, the difference between the
two ɑS-specific nanobodies suggests the influence of
other factors in the cell milieu in addition to the struc-
ture of ɑS oligomers. The lower protective effect of
NbSyn87 compared to NbSyn2 in these experiments
might be due to the high positive charge of NbSyn87
(pI > 9.0) and increased interaction with the cell mem-
branes, as well as due to its ability to abolish ɑS fibril
formation leading to the increased oligomer load. More
detailed comparison of the reduction of toxicity by
NbSyn2 and NbSyn87 in the cellular environment
remains to be made in future studies.
Finally, we tested whether or not the oligomers formed
in the presence of the ɑS-specific nanobodies reduced
the pro-inflammatory activation of microglial cells by
quantifying the concentration of the released pro-
inflammatory cytokine, the tumor necrosis factor alpha
(TNF-ɑ) protein [43], upon their incubation with ɑS
solutions after aggregation for 29 h. The experimental
procedure is described in Additional file 2: Supplementary
Information, and the results show that the application of
ɑS solutions aggregated with NbSyn2 and NbSyn87
resulted in a significantly reduced activation of microglia
in comparison to ɑS alone and/or NbHul5g-containing
samples (Fig. 4e).
Taken together, the comparative assays in Fig. 4 indicate
a lower average stability of the ɑS oligomer populations
generated in the presence of the ɑS-specific nanobodies
and a reduced propensity to cause cellular damage. These
findings are completely consistent with the conclusion
that the population of the more toxic high-FRET oligomer
type is reduced during the aggregation process of ɑS in
the presence of NbSyn87 and NbSyn2.
Discussion
In this study, we have characterized the key molecular
steps that are altered by the ɑS-specific nanobodies,
NbSyn2 and NbSyn87, during the aggregation reaction of
ɑS. We have observed a clear effect of NbSyn2 and
NbSyn87 on the formation of ɑS fibrils and their resulting
morphology. In addition, using single-molecule fluores-
cence measurements we have identified a selective action
of the nanobodies at the earliest stages of the aggregation
reaction associated with the formation of toxic oligomeric
species. In particular, both nanobodies were found to slow
down the conformational conversion from less stable low-
FRET oligomers to more stable high-FRET oligomers.
Moreover, we observed that both NbSyn2 and NbSyn87
are able rapidly to convert pre-formed high-FRET oligo-
mers to low-FRET species, indicating that the high-FRET
oligomers are destabilized upon the binding of these
nanobodies. These effects are associated with a significant
reduction of cytotoxicity induced by the oligomers.
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The ability of the nanobodies to promote the direct
conformational conversion from more toxic to less toxic
oligomeric species demonstrated in this study indicates
the existence of an influential and unexplored mode of
action of nanobodies or antibodies. Previously estab-
lished modes of action of antibodies and nanobodies in
vitro have included those that alter the equilibrium be-
tween fibrils, oligomers, and monomers [44], which can
take a finite length of time to make sufficient changes in
oligomer concentrations, and those that target oligomers
to decrease their binding to cell membranes [11, 45].
The rapid conformational conversion by nanobodies of
toxic oligomers to less toxic oligomers identified in our
experiments has a direct effect on their ability to cause
cellular damage. The results suggest, therefore, that the
ability of nanobodies to promote conformational conver-
sion of oligomers could have important potential for the
development of therapeutic strategies. Since our study
has been performed in vitro and at high concentrations
of ɑS, it will be of interest to elucidate the role of this
mechanism under a more complex biological environ-
ment in vivo in future investigations.
The ability of the nanobodies to destabilize high-FRET
oligomers observed here may be due to a combination of
their significantly smaller size than conventional anti-
bodies [31] and their binding to the accessible C-terminal
region of the protein [33, 34]. Antibodies binding to the
C-terminal region of ɑS have previously been shown to
decrease the production of highly aggregation-prone trun-
cated forms of ɑS lacking the C-terminal region [46].
Thus, steric effects could be an important feature in enab-
ling the smaller nanobodies to interact more effectively
with oligomers than larger antibodies and further com-
parison of the action of nanobodies and conventional anti-
bodies is warranted. Optimization of this destabilization
effect in future work by probing the nanobody binding site
in further detail may be possible through approaches that
can distinguish between different oligomer structures, and
hence measure the extent of destabilization.
Conclusions
This study has involved the detailed biophysical
characterization of the role of ɑS-specific nanobodies on
the aggregation of ɑS in vitro, including the use of
single-molecule fluorescence techniques. It shows that
nanobodies targeting the C-terminal region inhibit the
aggregation of ɑS not only by inhibiting its aggregation
and elongation processes, but also by inhibiting the
conformational conversion of oligomers formed prior to
fibril formation. The latter effect leads to the decrease in
oligomer stability and significantly reduces the cellular
damage resulting from the effects of oligomeric species.
Our work reveals an important mode of action of nano-
bodies, namely their ability rapidly to convert already
formed toxic oligomers to less toxic ones. Such a mode
of action has the potential to form the basis for a thera-
peutic strategy to combat PD and related protein
misfolding conditions.
Methods
Expression and purification of nanobodies and ɑS
NbSyn87, NbSyn2, and NbHul5g were expressed in the
periplasm of E. coli cells and purified using immobilized
metal affinity chromatography and size-exclusion chro-
matography as previously described [33]. The amino acid
sequences of NbSyn87 and NbSyn2 were as previously
reported [34]. The sequence and structure of NbHul5g
and the details of the construction of its more stable
variant NbHul5g has been previously reported [39]. Ex-
pression and purification of wt and the alanine to cyst-
eine mutant at position 90 (A90C) ɑS were carried out
according to published protocols [47].
ThT aggregation assays
Solutions of 600 μL of wt ɑS at a concentration of 70 μM
either with or without 2 molar equivalents of NbSyn87,
NbSyn2, or NbHul5g in PBS buffer (10 mM phosphate,
pH 7.5, 100 mM NaCl, 2 mM EDTA, and 0.1% NaN3)
were incubated for a period of 107 h at 37 °C with con-
stant agitation at 200 rpm (New Brunswick Scientific
Innova 43). Aliquots of 5 μL were removed at various time
points and added to a 95 μL ThT solution (20 μM) in PBS
buffer. ThT fluorescence was measured using a Cary
Eclipse fluorimeter (Varian) with excitation and emission
wavelengths of 440 and 480 nm, respectively. The mean
maximum intensities from triplicate measurements were
reported.
AFM measurements
The end-point samples from the aggregation procedures
used for the ThT assay were visualized using AFM
imaging. Cleaved mica surfaces were incubated for 1
min with 10 μL of 0.5% (v/v) (3-aminopropyl)triethoxysi-
lane (Sigma-Aldrich) in deionized water (Milli-Q). Then,
the surfaces were rinsed three times with 1 mL of deion-
ized water (Milli-Q) and dried with a gentle stream of
nitrogen. For each sample, 10 μL of the solution was
deposited on the positively functionalized surface. The
droplet was incubated for 10 min, then rinsed with 1 mL
of deionized water (Milli-Q) and dried with a gentle
stream of nitrogen; all procedures were carried out at
room temperature. AFM maps were acquired using JPK
Nanowizard 2 system operating in tapping mode and
equipped with a silicon tip (Micromasch, 2 Nm–1) with
a nominal radius of 10 nm. Image flattening was
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performed by SPIP (Image Metrology) software. Analysis
of mean fibril heights was carried out as previously
reported [48] and described in detail in Additional file 2:
Supplementary Information.
ɑS labeling
The A90C mutant variant of ɑS was labeled with either
maleimide-modified AF488 or AF594 dyes (Life Technolo-
gies) via the cysteine thiol moiety as previously reported
[13, 49]. The labeled protein was purified from the excess
of free dye using a P10 desalting column with Sephadex
G25 matrix (GE Healthcare) and concentrated using Ami-
con Ultra Centricons (Millipore), divided into aliquots,
flash frozen and stored at −80 °C. Each aliquot was thawed
immediately and used only once.
Estimation of the concentration of free ɑS
The concentration of free ɑS was estimated as the differ-
ence between the total starting concentration of ɑS and
the concentration of bound ɑS in the presence of nano-
bodies, calculated according to:
as½ bound ¼
1
2

as½  þ Nb½  þ Kd
−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
as½  þ Nb½  þ Kdð Þ2−4 as½  Nb½ 
q
Þ
ð1Þ
where [as]bound is the concentration of bound ɑS, [as]
and [Nb] are the starting concentrations of ɑS and nano-
body, and Kd is the corresponding dissociation constant
[34].
Sm-FRET experiments
The experiments were carried out according to previ-
ously published procedures [37, 38], utilizing a custom-
built single-molecule setup as already described [50] and
microfluidic devices fabricated as previously reported
[38]. The single-molecule instrumentation has been
previously described in detail [37]. For the aggregation
reactions, equimolar concentrations of AF488- and
AF594-labeled A90C ɑS (AF488-ɑS and AF594-ɑS) in
PBS were combined to a final volume of 300 μL, bring-
ing the total ɑS concentration to 70 μM, either in the
presence or absence of 140 μM of unlabeled NbSyn87,
NbSyn2, or NbHul5g. At least three separate samples
were prepared and analyzed at each protein combin-
ation. The solutions were incubated in the dark for up
to 50 h under the same incubation conditions as the
samples for ThT assays (37 °C, with agitation). Aliquots
were withdrawn at regular time intervals and diluted
2.5 × 105 fold by serial dilution in either PBS buffer or
deionized water (Milli-Q) to give a concentration
suitable for analysis in the single molecule regime. Im-
mediately upon dilution, the solution was passed at a
constant rate of 2 cm s–1 (syringe pump PHD2000,
Harvard Apparatus) through a channel of a microfluidic
device mounted on the single-molecule confocal micro-
scope (Nikon Eclipse Ti-U). The 488 nm laser beam was
focused into the center of the channel (10 μm along ver-
tical direction). The experimental data consisted of syn-
chronous time-binned fluorescence output from the
donor (AF488) and the acceptor (AF594) channels,
acquired for 400 s per aliquot (80 frames, 100,000 bins
frame–1, 50 μs bin-width). The absence of oligomer
dissociation during sm-FRET detection was previously
confirmed [37], and the estimated oligomer concentra-
tions were previously found to agree with the oligomer
concentrations at bulk conditions [13].
Sm-FRET data analysis
The resulting sm-FRET data were analyzed as previously
reported [37, 38], using custom-written Igor Pro code
(Wavemetrics). Time-bins with intensities above 15
photons.bin–1 were selected in both the donor and
acceptor channel (AND criterion) [51]. Simultaneous
fluorescence bursts above the threshold were assigned to
oligomeric events and the non-simultaneous donor
bursts above the threshold correspond to monomeric
ɑS. The intensities of the selected photon bursts were
corrected for the crosstalk from donor to acceptor chan-
nel (13%), and the autofluorescence in the acceptor
channel (1.3 photons.bin–1). For each oligomeric burst,
the two key parameters calculated were the apparent size
of the oligomer (Size) and the FRET efficiency (E),
defined as:
E ¼ IA
IA þ γID ð2Þ
Size ¼ 2 ID þ γ
−1IA
Imonomer
ð3Þ
where ID is the donor intensity in the presence of an
acceptor, IA is the acceptor intensity, γ is the gamma
factor, which corrects for the differences in detection
efficiencies of the two fluorescent probes and their
quantum yields ( γ = 0.99), and Imonomer is the mean
monomer brightness, averaged over all of the non-
coincident bursts in the donor channel. FRET efficiency
and apparent size distributions were represented as his-
tograms with bin-widths of 0.05 and 1, respectively. The
presence of undetectable singly-colored or fluorescently
quenched oligomers was assumed to have no significant
effect on the data, based on our previous works [13, 38].
Large species, either those apparently greater than 150
monomers in size or occupying consecutive time-bins,
Iljina et al. BMC Biology  (2017) 15:57 Page 11 of 14
were assumed to be due to fibrillar species and were
excluded from the analysis, as reported in our previous
study [38]. Subsequently, both the monomer and the
oligomer bursts were converted into corresponding bulk
ɑS concentrations by taking into account the dilution
factor, as previously reported [37].
Additional files
Additional file 1: Figure S1. Additional results. (a) AFM images of
starting monomeric solutions of wild-type (wt) ɑS prior to incubation with agi-
tation. (b) Total internal reflection fluorescence microscopy results. Left: repre-
sentative sum-image in the ThT emission channel (100 frames) and the
corresponding reconstruction image in the NR channel (2000 frames).
Right: comparison of the total numbers of aggregates and percent of
ThT-active aggregates formed in the wt ɑS-only and wt ɑS + nanobody
solutions at the same time-point of the aggregation process. (c) Scatter
plots and statistical comparison of the distributions of average fibril
heights derived from AFM maps (Fig. 1b, c, main text). (d) Quartz crystal
microbalance recordings using ɑS (21 μM), nanobody alone (21 μM) or
1:1 mixture of ɑS with nanobody (21 μM : 21 μM) or control peptide
(42 μM). (TIF 4648 kb)
Additional file 2: Supplementary Information. (PDF 462 kb)
Additional file 3: Figure S2. Results of control bulk ThT experiments
and TEM imaging of labeled ɑS. (a) Progression of fibril formation,
monitored by ThT fluorescence emission from either unlabeled wild-type
(black) or AF-594 labeled ɑS at 70 μM (n = 3, SD). (b) TEM images of aggre-
gates formed in 70 μM 1:1 AF488:AF594 dual-labeled ɑS solutions. Top: la-
beled ɑS solutions at different time-points during aggregation.
Bottom: ɑS solutions in the presence of 140 μM of unlabeled NbHul5g,
NbSyn2, and NbSyn87 after more than 100 h incubation with agitation.
Large amyloid fibrils and fibrillar fragments were observed in all samples at
this time, except in the presence of NbSyn87, where short protofibrils were
present along with oligomeric aggregates. (TIF 4331 kb)
Additional file 4: Figure S3. Kinetic analysis of ɑS aggregation. (a)
Schematic representation of the nucleation-conversion-polymerization
model. Monomeric ɑS form low-FRET oligomers with rate constant kn
and an average reaction order nc. Low-FRET oligomers convert into high-
FRET oligomers by a first-order reaction with a rate constant k1
c, which is
followed by a first-order conversion to fibrils, with a rate constant k2
c.
Once formed, fibrils grow by monomer addition with a length-
independent rate constant ke. The conversion steps between oligomer
types are treated as size independent, and k1
c is set to be equal to k2
c.
First-order reverse conversion reactions from high-FRET to low-FRET oligo-
mers and from low-FRET oligomers to monomers are introduced, with rate
constants kc1
˜ and kn
˜ , respectively. (b–e) This model was fitted globally to
the kinetic data of ɑS aggregation at 70 μM in the absence or the
presence of 140 μM of nanobodies. The global fits (dashed lines)
were performed with parameters kn = (1.0 ± 0.5) × 10
− 3 h− 1, ke = 0.16
± 0.08 μM− 1h− 1, k1c = k2c = 0.12 ± 0.04 h− 1, kn˜ ¼ kc1˜ ¼ 0h1, nc = 1 ±
0.1, mtot = 70 μM for reactions containing ɑS only and ɑS with
NbHul5g. The reverse reaction from high-FRET oligomers to low-FRET
oligomers was found to be accelerated in the presence of NbSyn2
and NbSyn87, with kn
˜ ¼ 0:2 0:1h1 and kc1˜ ¼ 1 0:5h1 for ɑS
aggregation in the presence of NbSyn2, and with kn
˜ ¼ 0:25 0:1h1
and kc1
˜ ¼ 10 5h1 for ɑS aggregation in the presence of NbSyn87, with
all remaining parameters unchanged. (f) Predictions of the concentrations
of low-FRET and high-FRET oligomers during 100 h of ɑS aggregation in the
presence or absence of nanobodies. (TIF 710 kb)
Additional file 5: Figure S4. Representative FRET efficiency histograms
from the ‘reverse’ sm-FRET experiments, analogous to those shown in
Fig. 3 (main text). (a) Pre-formed high-FRET oligomers were formed in a
forward incubation of monomeric ɑS (70 μM in PBS, 29 h, shaking at 37 °C).
To the pre-formed oligomer solutions, either 1, 0.5, or 0.25 molar equivalents
of nanobodies, NbSyn87 (b) or NbSyn2 (c), were added and sm-FRET detec-
tion was carried out within 5 min after the addition. In the case of 0.25
equivalents, the samples were further incubated at 37 °C under quies-
cent conditions (in low-binding test-tubes), and sm-FRET analysis repeated.
(TIF 877 kb)
Additional file 6: Figure S5. Representative contour plots of FRET
efficiency and size after proteinase K digestion of 29-h time-points by differ-
ent concentrations of proteinase K (Fig. 4a, main text). (a) Control sample
containing NbHul5g is less degradable in comparison to the samples pre-
pared in the presence of NbSyn2 (b) and NbSyn87 (c), as indicated by the
presence of higher oligomer fraction remaining in the sample upon incuba-
tion with proteinase K. This is consistent with the presence of high-FRET olig-
omers in the sample. (TIF 1028 kb)
Additional file 7: Supporting Data Values. (XLSX 27 kb)
Additional file 8: Figure S6. Representative result from the reactive
oxygen species measurements presented in main text, Fig. 4c. Application
of 500 nM of AF-labeled ɑS solution induced an increase in the ratio of
dihydroethydium (HEt) fluorescence between its oxidized and non-oxidized
forms. The time when ɑS was applied is marked with the grey bracket on
the plot. A higher increase in HEt ratio is observed upon application of ɑS
solutions containing control NbHul5g, suggesting that oligomers formed in
its presence are more damaging in comparison to the oligomers formed in
the presence of ɑS-specific nanobodies. (TIF 108 kb)
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